Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate ...

By focusing on a non-PSMA target, we also believe ATNM-400 has the potential to address some of the toxicities reported with Pluvicto and other PSMA targeting radiotherapies such as xerostomia.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.

By focusing on a non-PSMA target, we also believe ATNM-400 has ... A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting ...

Once bound, the beta-minus emission from lutetium-177 delivers radiation to PSMA-expressing cells as well ... Criteria in Solid Tumors (RECIST) v1.1 criteria. Findings showed treatment with ...